Defence's mRNA with Accum(TM) for Cancer Vaccines Update
Vancouver, British Columbia--(Newsfile Corp. - December 15, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is currently working on combining its AccumTM technology with mRNA vaccination as previously announced in press release dated of October 31st, 2022. This R&D program will not only impact the field of...
2022-12-15 3:15 AM EST
Defence Therapeutics Appoints Kwin Grauer to Its Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - December 9, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the appointment of Mr. Kwin Grauer to its board of directors, effective immediately.Mr. Kwin Grauer, CPA, CA, has more than 20 years' experience operating, buying and selling small...
2022-12-09 3:30 PM EST
Defence Positioned to Begin Its Anti-Cancer AccuTOX(TM) Phase I Trial with Successful Completion of GLP Studies
Vancouver, British Columbia--(Newsfile Corp. - December 6, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the successful completion of all GLP studies related to its anti-cancer AccuTOXTM molecule. The Company is planning to meet with the FDA in the weeks to come to obtain approval for...
2022-12-06 3:15 AM EST
Defence's Successfull Study on the AccuVAC-PT007 Vaccine Targeting Cervical Cancer
Vancouver, British Columbia--(Newsfile Corp. - November 23, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the successful completion of its Good Laboratory Practice ("GLP") studies on the AccuVAC-PT007 vaccine candidate specifically designed to target cervical cancer. GLP studies conducted...
2022-11-23 3:15 AM EST
Defence Therapeutics Completes Fully-Subscribed Debenture Financing of $2,355,000
Vancouver, British Columbia--(Newsfile Corp. - November 16, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the closing of its previously announced non-brokered private placement of debenture units (the "Units") at a price of $1,000 per Unit for aggregate gross proceeds of $2,355,000 (the...
2022-11-16 6:00 PM EST
mRNA Program: Defence to Apply Its Propriatry Accum(TM) Technology in The Design of Messenger RNA Anti-Cancer Vaccines
Vancouver, British Columbia--(Newsfile Corp. - October 31, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is initiating a new research and development program designed to exploit the AccumTM technology in engineering messenger (m)RNA vaccines targeting cancer. AccumTM is designed for intracellular accumulation...
2022-10-31 3:15 AM EDT
Defence Therapeutics Announces Debenture Financing
Vancouver, British Columbia--(Newsfile Corp. - October 28, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce a non-brokered private placement of debenture units (the "Units") at a price of $1,000 per Unit for aggregate gross proceeds of up to $2,355,000 (the "Offering"). Each Unit will...
2022-10-28 6:00 PM EDT
Defence Therapeutics Initiates Lung Cancer Treatment Program with Its Novel AccuTOX(TM) Formulation via Intranasal
Vancouver, British Columbia--(Newsfile Corp. - October 12, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the start of a pre-clinical program using its novel patent pending technology AccuTOXTM. The novel AccuTOXTM formulation is designed for the treatment of lung cancer including various...
2022-10-12 3:15 AM EDT
Defence Therapeutics Is Granted Patents in Japan and Israel Expanding Its Novel ADC Platform Technology in the Fast Growing Antibody-Drug Conjugates Market
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate ("ADC"), is pleased to announce that a notice of allowance has been issued by the Japan Patent Office for its Japanese patent application no. 2018-568469. In...
2022-09-29 3:15 AM EDT
Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma
Vancouver, British Columbia--(Newsfile Corp. - September 21, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report that Defence's novel vaccine candidate triggers a potent anti-tumoral response capable of curing animals with pre-established lymphoma.Antigen presentation is a crucial step for the...
2022-09-21 3:15 AM EDT
Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative
Vancouver, British Columbia--(Newsfile Corp. - September 16, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biotech company actively working on accelerating scientific discoveries and products development against cancer, congratulates the US President Joe Biden for the executive order signed on Monday establishing the Biotechnology and Biomanufacturing initiative to ensure cutting-edge biotechnologies necessary to end cancer...
2022-09-16 2:00 PM EDT
Breakthrough Discovery: Defence's Accum(TM) Variant "A1" Converts Mesenchymal Stromal Cells into Potent Antigen Presenting Cells Suitable for Cancer Vaccination
Vancouver, British Columbia--(Newsfile Corp. - August 17, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the development of a novel anti-cancer cellular vaccine by reprogramming the unconventional suppressive mesenchymal stromal cells (MSCs) into potent antigen presenting cells (APCs). The...
2022-08-17 3:15 AM EDT
Defence Therapeutics Receives U.S. Patent Covering Its ADC Platform Technology
Vancouver, British Columbia--(Newsfile Corp. - August 8, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate ("ADC"), is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted Defence Therapeutics Inc. the U.S. patent no....
2022-08-08 3:15 AM EDT
Breakthrough Discovery: AccuTOX(TM) Effectively Kills Cancer Cells by Directly Eliciting DNA Damage
Vancouver, British Columbia--(Newsfile Corp. - August 2, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the discovery of a novel DNA damaging function triggered by one of its lead compounds AccuTOXTM, which effectively elicits cell death in cancer cells.Cancer can be generally described as...
2022-08-02 3:15 AM EDT
Defence's Accum(TM) with Antibody Drug Conjugates (ADC) in Development Against Cancer
Vancouver, British Columbia--(Newsfile Corp. - July 5, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to provide an update on its ADC programs in development using Defence's AccumTM, including key in vivo studies with worldwide collaborators. The world-renowned Curie Institute, one of Defence's...
2022-07-05 3:15 AM EDT
Defence Reports Effective Control of Cervical Cancer Growth in Response to Its AccuVAC-PT007 Therapeutic Vaccination
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report potent pre-clinical results on the use of its AccumTM-linked protein vaccine, AccuVAC-PT007, against cervical cancer. Cervical cancer is a type of cancer affecting the cervix. Various...
2022-06-27 3:15 AM EDT
RETRANSMISSION: Defence's Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from Cervical Cancer
The Company is issuing a clarification news release at the request of IIROC.Vancouver, British Columbia--(Newsfile Corp. - May 18, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focused on the development of novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the development of novel dual-acting AccumTM-linked protein vaccine, AccuVAC-PTE7, dedicated to...
2022-05-18 11:30 AM EDT
Defence Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from Cervical Cancer
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the development of novel dual-acting AccumTM-linked protein vaccine, AccuVAC-PTE7, dedicated to protect from cervical cancer (prophylactic vaccine) or to treat (therapeutic...
2022-05-17 4:30 PM EDT
Defence Therapeutics Announces Issuance Of a U.S. Patent Covering Its Pioneering Vaccine Platform Technology
Vancouver, British Columbia--(Newsfile Corp. - April 7, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company primarily focused on the development of novel vaccines and drug delivery technologies, is pleased to announced that the United States Patent and Trademark Office (USPTO) has granted patent number US 11,291,717 ('717) covering its breakthrough vaccine platform technology for the treatment/prevention...
2022-04-07 3:15 AM EDT
Defence Therapeutics: An Anti-Cancer Solutions Platform Company Advancing Its Versatile Accum Technology
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF)("Defence" or the "Company"), a Canadian biotech company actively working on accelerating scientific discoveries and products development against cancer, is pleased to provide an overview of its current research and development progress in various cancer activities. In Q1 of 2022, Defence has signed an agreement with the Advanced Therapies Facilities (ATF) - GMP...
2022-03-22 3:15 AM EDT